Centessa Pharmaceuticals PLC (CNTA)
8.63
+0.51
(+6.28%)
USD |
NASDAQ |
May 31, 16:00
8.62
-0.01
(-0.12%)
After-Hours: 20:00
Centessa Pharmaceuticals Enterprise Value: 822.19M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 822.19M |
| May 30, 2024 | 764.54M |
| May 29, 2024 | 755.50M |
| May 28, 2024 | 762.28M |
| May 24, 2024 | 781.50M |
| May 23, 2024 | 790.54M |
| May 22, 2024 | 835.76M |
| May 21, 2024 | 818.80M |
| May 20, 2024 | 832.37M |
| May 17, 2024 | 849.33M |
| May 16, 2024 | 858.37M |
| May 15, 2024 | 840.28M |
| May 14, 2024 | 868.54M |
| May 13, 2024 | 844.80M |
| May 10, 2024 | 860.63M |
| May 09, 2024 | 926.20M |
| May 08, 2024 | 918.28M |
| May 07, 2024 | 939.76M |
| May 06, 2024 | 892.28M |
| May 03, 2024 | 917.15M |
| May 02, 2024 | 913.00M |
| May 01, 2024 | 905.18M |
| April 30, 2024 | 869.45M |
| April 29, 2024 | 878.90M |
| April 26, 2024 | 837.78M |
| Date | Value |
|---|---|
| April 25, 2024 | 743.93M |
| April 24, 2024 | 797.18M |
| April 23, 2024 | 791.15M |
| April 22, 2024 | 851.44M |
| April 19, 2024 | 908.72M |
| April 18, 2024 | 904.70M |
| April 17, 2024 | 929.82M |
| April 16, 2024 | 954.94M |
| April 15, 2024 | 929.82M |
| April 12, 2024 | 984.08M |
| April 11, 2024 | 1.039B |
| April 10, 2024 | 967.00M |
| April 09, 2024 | 982.57M |
| April 08, 2024 | 926.80M |
| April 05, 2024 | 926.80M |
| April 04, 2024 | 888.62M |
| April 03, 2024 | 933.84M |
| April 02, 2024 | 985.08M |
| April 01, 2024 | 959.96M |
| March 28, 2024 | 952.61M |
| March 27, 2024 | 932.55M |
| March 26, 2024 | 898.44M |
| March 25, 2024 | 973.67M |
| March 22, 2024 | 1.043B |
| March 21, 2024 | 1.031B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-170.61M
Minimum
Jun 06 2022
2.256B
Maximum
Jun 17 2021
457.56M
Average
384.47M
Median
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 142.58M |
| Biodexa Pharmaceuticals Plc | 1.860M |
| Verona Pharma PLC | 772.32M |
| NuCana PLC | -8.064M |
| Autolus Therapeutics PLC | 356.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.05M |
| Total Expenses (Quarterly) | 36.09M |
| EPS Diluted (Quarterly) | -0.38 |
| Earnings Yield | -16.34% |